Acelyrin, Inc. (NASDAQ:SLRN – Free Report) – Research analysts at HC Wainwright lowered their FY2023 earnings estimates for shares of Acelyrin in a report released on Wednesday, November 8th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($10.66) for the year, down from their previous forecast of ($9.60). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Acelyrin’s current full-year earnings is ($6.66) per share. HC Wainwright also issued estimates for Acelyrin’s Q4 2023 earnings at ($0.78) EPS, FY2024 earnings at ($3.61) EPS, FY2025 earnings at ($5.13) EPS, FY2026 earnings at ($4.71) EPS and FY2027 earnings at ($3.82) EPS.
Acelyrin (NASDAQ:SLRN – Get Free Report) last released its earnings results on Monday, August 14th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.25.
Acelyrin Stock Performance
SLRN opened at $8.02 on Friday. The firm has a 50 day moving average of $12.31. Acelyrin has a 1-year low of $7.68 and a 1-year high of $29.88.
Institutional Investors Weigh In On Acelyrin
Hedge funds have recently made changes to their positions in the stock. AyurMaya Capital Management Company LP acquired a new stake in Acelyrin during the 2nd quarter worth approximately $195,096,000. venBio Partners LLC acquired a new stake in Acelyrin during the 2nd quarter worth approximately $80,616,000. JPMorgan Chase & Co. acquired a new stake in Acelyrin during the 2nd quarter worth approximately $77,400,000. CHI Advisors LLC acquired a new stake in Acelyrin during the 2nd quarter worth approximately $55,674,000. Finally, Samsara BioCapital LLC acquired a new stake in Acelyrin during the 2nd quarter worth approximately $47,151,000. 94.68% of the stock is currently owned by institutional investors and hedge funds.
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
- Five stocks we like better than Acelyrin
- Best Stocks Under $5.00
- Data giants MongoDB and Snowflake just got upgraded
- How Can Investors Benefit From After-Hours Trading
- Plug Power at tipping point; it’s make or break time for hydrogen
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for Acelyrin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acelyrin and related companies with MarketBeat.com's FREE daily email newsletter.